论文信息 - Avelumab (MSB0010718C; anti-PD-L1) in patients with metastatic urothelial carcinoma from the JAVELIN solid tumor phase 1b trial: Analysis of safety, clinical activity, and PD-L1 expression. - 字舞流文

Avelumab (MSB0010718C; anti-PD-L1) in patients with metastatic urothelial carcinoma from the JAVELIN solid tumor phase 1b trial: Analysis of safety, clinical activity, and PD-L1 expression.

A. Ravaud | K. Kelly | T. Stinchcombe | H. Safran | C. Britten | J. Infante | A. Heydebreck | A. Mita | A. Apolo | O. Hamid | A. Mega | J. Gulley | H. Grote | Ding Wang | J. Cuillerot | M. Patel | A. V. Heydebreck